Mobile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary...

Update Il y a 4 ans
Reference: EUCTR2008-004405-34

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF)

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of the study is to determine if ambrisentan is effective in delaying disease progression and death in subjects with IPF.

Inclusion criteria

  • Idiopathic Pulmonary Fibrosis (IPF)

Links